247 related articles for article (PubMed ID: 11823957)
1. Daily dosing of highly active antiretroviral therapy.
Rosenbach KA; Allison R; Nadler JP
Clin Infect Dis; 2002 Mar; 34(5):686-92. PubMed ID: 11823957
[TBL] [Abstract][Full Text] [Related]
2. Once-a-day therapy for HIV infection: a controlled, randomized study in antiretroviral-naive HIV-1-infected patients.
Maggiolo F; Ripamonti D; Gregis G; Quinzan G; Callegaro A; Arici C; Ravasio L; Suter F
Antivir Ther; 2003 Aug; 8(4):339-46. PubMed ID: 14518703
[TBL] [Abstract][Full Text] [Related]
3. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
[TBL] [Abstract][Full Text] [Related]
4. Once-daily therapies.
Carey D
J HIV Ther; 2003 Feb; 8(1):7-11. PubMed ID: 12840708
[TBL] [Abstract][Full Text] [Related]
5. Impact of once- and twice-daily dosing regimens on adherence and overall safety.
Hawkins T
AIDS Read; 2004 Jun; 14(6):320-2, 324, 329-31, 334-6. PubMed ID: 15243968
[TBL] [Abstract][Full Text] [Related]
6. Once-daily dosing of nevirapine in HAART.
Clotet B
J Antimicrob Chemother; 2008 Jan; 61(1):13-6. PubMed ID: 18006524
[TBL] [Abstract][Full Text] [Related]
7. Initiation of antiretroviral therapy: implications of recent findings.
Saag MS
Top HIV Med; 2004; 12(3):83-8. PubMed ID: 15310939
[TBL] [Abstract][Full Text] [Related]
8. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors.
Maggiolo F; Ravasio L; Ripamonti D; Gregis G; Quinzan G; Arici C; Airoldi M; Suter F
Clin Infect Dis; 2005 Jan; 40(1):158-63. PubMed ID: 15614706
[TBL] [Abstract][Full Text] [Related]
9. Simplifying antiretroviral therapy.
Tapper ML; Flexner C; Eron JJ; Molina JM
AIDS Read; 2004 Jul; 14(7):355-60, 367-71. PubMed ID: 15282865
[TBL] [Abstract][Full Text] [Related]
10. Adherence to antiretroviral regimens in HIV-infected patients: results of a survey among physicians and patients.
Gallant JE; Block DS
J Int Assoc Physicians AIDS Care; 1998 May; 4(5):32-5. PubMed ID: 11365186
[TBL] [Abstract][Full Text] [Related]
11. A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection.
Cardiello PG; Hassink E; Ananworanich J; Srasuebkul P; Samor T; Mahanontharit A; Ruxrungtham K; Hirschel B; Lange J; Phanuphak P; Cooper DA
Clin Infect Dis; 2005 Feb; 40(4):594-600. PubMed ID: 15712083
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.
Gatell J; Salmon-Ceron D; Lazzarin A; Van Wijngaerden E; Antunes F; Leen C; Horban A; Wirtz V; Odeshoo L; Van den Dungen M; Gruber C; Ledesma E;
Clin Infect Dis; 2007 Jun; 44(11):1484-92. PubMed ID: 17479947
[TBL] [Abstract][Full Text] [Related]
13. Alternation of antiretroviral drug regimens for HIV infection. Efficacy, safety and tolerability at week 96 of the Swatch Study.
Negredo E; Paredes R; Peraire J; Pedrol E; Côté H; Gel S; Fumoz CR; Ruiz L; Abril V; Rodriguez de Castro E; Ochoa C; Martinez-Picado J; Montaner J; Rey-Joly C; Clotet B;
Antivir Ther; 2004 Dec; 9(6):889-93. PubMed ID: 15651747
[TBL] [Abstract][Full Text] [Related]
14. Genotypic resistance tests for the management of patients at simplification of highly active antiretroviral therapy.
Suter F; Ghinelli F
Scand J Infect Dis Suppl; 2003; 106():82-5. PubMed ID: 15000592
[TBL] [Abstract][Full Text] [Related]
15. Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy.
Lima VD; Gill VS; Yip B; Hogg RS; Montaner JS; Harrigan PR
J Infect Dis; 2008 Jul; 198(1):51-8. PubMed ID: 18498238
[TBL] [Abstract][Full Text] [Related]
16. Mutation and control of the human immunodeficiency virus.
Stengel RF
Math Biosci; 2008 Jun; 213(2):93-102. PubMed ID: 18439629
[TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy and safety of twice-daily saquinavir soft gelatin capsules (SGC), with or without nelfinavir, and three times daily saquinavir-SGC, in triple combination therapy for HIV infection: 100-week follow-up.
Greenberg RN; Feinberg J; Goodrich J; Pilson RS; Siemon-Hryczyk P
Antivir Ther; 2003 Feb; 8(1):37-42. PubMed ID: 12713062
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of simplified protease inhibitor dosing regimens for the treatment of HIV infection.
Cohen CJ; Hellinger J; Norris D
AIDS Read; 2000 May; 10(5):296-9, 304-7, 311-3. PubMed ID: 10851721
[TBL] [Abstract][Full Text] [Related]
19. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
[TBL] [Abstract][Full Text] [Related]
20. Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program.
Jaspan HB; Berrisford AE; Boulle AM
Pediatr Infect Dis J; 2008 Nov; 27(11):993-8. PubMed ID: 18818556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
